Remimazolam (Byfavo)

About Paion

PAION AG was a publicly listed German biopharmaceutical company focused on hospital-based sedation, anesthesia, and critical care. Its core achievement was the development and global regulatory approval of remimazolam, a novel, controllable benzodiazepine sedative. The company pursued a hybrid strategy of internal development and strategic in-licensing (e.g., GIAPREZA, XERAVA) but ultimately entered insolvency proceedings in January 2024, leading to the sale of its operating assets to a new entity, PAION Pharma GmbH.

About Paion

PAION AG was a publicly listed German biopharmaceutical company focused on hospital-based sedation, anesthesia, and critical care. Its core achievement was the development and global regulatory approval of remimazolam, a novel, controllable benzodiazepine sedative. The company pursued a hybrid strategy of internal development and strategic in-licensing (e.g., GIAPREZA, XERAVA) but ultimately entered insolvency proceedings in January 2024, leading to the sale of its operating assets to a new entity, PAION Pharma GmbH.

About Cosmo Pharmaceuticals

Cosmo Pharmaceuticals has successfully transitioned from an R&D-focused venture to a hybrid commercial organization with a mission to develop and commercialize innovative treatments for gastrointestinal diseases, dermatology, and colorectal cancer. Its core achievement is the proprietary MMX® technology, enabling targeted colonic drug delivery, which underpins its flagship products and pipeline. The company's strategy combines direct commercialization in key markets with strategic out-licensing and partnerships to maximize global reach and capital efficiency while advancing a pipeline of novel GI and dermatology assets.

Therapeutic Areas